AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 201 min read$CERS

Jayaraman Vivek K sold $53K of CERS

Jayaraman Vivek K (Chief Executive Officer) sold 16,666 shares of CERUS CORP (CERS) at $3.16 on 2026-07-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Jayaraman Vivek K
Published Jul 20, 2026, 9:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 20, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CERS
Neutral
high confidence
Mentioned
$CERS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CERSNeutralLow
01

Why it matters

The newest concrete fact is the CEO’s open-market sale size, price, and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note insider selling, but the 10b5-1 designation reduces the signal strength versus unscheduled sales.

03

What to watch

The article does not state whether other insiders sold/bought, nor does it provide context on total CEO holdings over time beyond the post-transaction share count.

Relevance 2/10Novelty 3/10Timing: new Form 4 filed 2026-07-20, covering a sale dated 2026-07-16

Background

The article is a SEC Form 4 insider transaction disclosure for Cerus Corp, reported by the CEO.

Company-level read

Ticker impact

$CERSNeutralHigh confidence
Context

Cerus Corp CEO Jayaraman Vivek K filed a Form 4 selling 16,666 shares at $3.1600 on 2026-07-16 under a 10b5-1 plan.

Expected impact

Limited near-term impact; any effect is likely sentiment-only and typically fades unless paired with other negative news.

Evidence & confidence

The filing is a Form 4 open-market sale by the CEO, explicitly under a pre-arranged 10b5-1 plan, with no accompanying guidance, deal, or regulatory development in the text.

Market effects

Sector

No sector read-through provided; this is company-specific insider transaction data only.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

10b5-1 plans often reflect scheduled liquidity rather than bearish fundamentals, so the sale may be informationally weak.

Key entities

  • issuer
    Cerus Corp

    Company whose CEO reported an open-market sale on Form 4.

  • insider
    Jayaraman Vivek K

    CEO reporting the sale of 16,666 shares.

  • trading mechanism
    10b5-1 plan

    Pre-arranged plan noted as Yes in the filing.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CERS insider trading history →

Related articles

NOV 3
$CERSMed

Cerus Q3 Earnings Call Highlights

Cerus reported Q3 EMEA revenue growth of 5%, impacted by geopolitical and currency headwinds. The company's RedeS study met primary efficacy endpoints, with full analysis expected soon. Cerus reaffirmed 2026 revenue guidance of $229M-$231M and reported positive adjusted EBITDA. The company is addressing regulatory questions from the FDA and ANSM. Cerus aims for GAAP profitability and plans to refresh its shelf registration statement.

finance.yahoo.com2 min
NOV 2
$CERSMed

Cerus: Q3 Earnings Snapshot

Cerus Corp. reported a Q3 loss of $550,000, or less than 1 cent per share, with revenue of $57.7 million. The company expects full-year revenue between $229 million and $231 million.

finance.yahoo.com1 min
NOV 2
$CERSMedAI 8/10

Cerus' blood-safety system meets main goal in late-stage trial

Cerus Corp reported that its Intercept blood-safety technology met the main goal in a late-stage trial, showing treated red blood cells performed as well as conventional ones in transfusions. The study found no significant difference in adverse events, though some patients developed temporary antibodies. The technology is not yet FDA-approved.

finance.yahoo.com4 min
NOV 2
$CERSMed

Cerus Corporation Announces Third Quarter 2026 Financial Results

CERUS CORP (CERS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cerus Corporation Announces Third Quarter 2026 Financial Results Third quarter 2026 total revenue of $64.0 million; third quarter 2026 product revenue of $57.7 million, +10% Y/Y Announced positive topline Phase 3 RedeS results of the INTERCEPT Blood System for red bl

SEC EDGAR 8-K2 min
NOV 2
MedAI 8/10

Treated red blood cells performed no worse than conventional cells on hemoglobin gains in Cerus’ Phase 3 trial.

Cerus Corporation reported that its INTERCEPT Red Blood Cells (RBCs) met the primary efficacy endpoint in a Phase 3 trial, showing non-inferiority to conventional RBCs in adjusted hemoglobin increment. The study also met primary safety endpoints, with no significant differences in treatment-emergent adverse events between the treatment and control arms. Cerus plans to submit full study results for peer-reviewed publication and presentation at scientific meetings.

stocktitan.net2 min